Nelediaden (Atorvastatin)

Atorvastatin, the active ingredient in Nelediaden, is a HMG‑CoA reductase inhibitor presented as an oral tablet for systemic use. It lowers elevated cholesterol and triglyceride levels and is prescribed for adults with hypercholesterolemia, mixed dyslipidemia, or those at risk of cardiovascular events and helps to reduce the likelihood of heart attack or stroke.

GNH USA supplies Nelediaden as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across multiple regions.

Nelediaden (atorvastatin) is used to manage disorders of lipid metabolism and to lower cardiovascular risk. - Hypercholesterolemia: reduces low‑density lipoprotein (LDL) cholesterol to target levels. - Mixed dyslipidemia: lowers LDL and triglycerides while modestly raising high‑density lipoprotein (HDL) cholesterol. - Primary prevention of cardiovascular events: decreases the incidence of myocardial infarction, stroke and related vascular outcomes in patients at elevated risk.

Common and serious adverse reactions have been reported with atorvastatin therapy. Common Side Effects: - Headache: mild to moderate intensity. - Myalgia: muscle aches without weakness. - Gastrointestinal upset: nausea, abdominal discomfort or constipation. Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with possible renal injury. - Elevated liver enzymes: indicating hepatic stress or injury. - Severe allergic reaction: rash, angioedema or anaphylaxis.

When prescribing Nelediaden, clinicians should consider several safety precautions to minimize risk. - Liver function monitoring: assess transaminases before initiation and periodically during therapy. - Muscle symptom assessment: evaluate for unexplained muscle pain, tenderness or weakness. - Drug interaction review: avoid concomitant use with strong CYP3A4 inhibitors. - Renal impairment caution: adjust therapy in patients with severe kidney disease. - Pregnancy and lactation: discontinue if pregnancy is confirmed; safety in breastfeeding is unknown. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Atorvastatin may interact with other medicines, altering its efficacy or safety profile. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors): can markedly increase atorvastatin concentrations. - Gemfibrozil: raises risk of myopathy and rhabdomyolysis. - Cyclosporine: enhances statin exposure and muscle toxicity. Moderate Interactions (Monitor Closely): - Warfarin: may increase anticoagulant effect, requiring INR monitoring. - Digoxin: potential for increased serum levels. - Amiodarone: may modestly raise atorvastatin levels. - Niacin (high dose): adds to risk of hepatotoxicity and muscle effects.